Denna sida på svenska
Loading profile information...

About me

I defended my thesis on Immune modulation by mesenchymal stem cells in 2005. After that I worked for 3 years as a researcher at Uppsala University. Since October 2008 my main focus have been pharmaceutical development being employed at a biotech company in Uppsala. Since January 2017, I have been employed by KI working for Katarina Le Blanc to manage mainly clinical development including GMP production of MSC as advanced therapy.

Links

Publications

Mesenchymal stromal cells support endothelial cell interactions in an intramuscular islet transplantation model
Fransson M, Brännström J, Duprez I, Essand M, Le Blanc K, Korsgren O, et al
Regenerative medicine research 2015;3():1-

Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis
Fransson M, Piras E, Wang H, Burman J, Duprez I, Harris Ra, et al
Immunology 2014;142(3):431-41

Are therapeutic human mesenchymal stromal cells compatible with human blood?
Moll G, Rasmusson-duprez I, Von Bahr L, Connolly-andersen Am, Elgue G, Funke L, et al
Stem cells (Dayton, Ohio) 2012;30(7):1565-74

Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses
Moll G, Jitschin R, Von Bahr L, Rasmusson-duprez I, Sundberg B, Lönnies L, et al
PloS one 2011;6(7):e21703-

Complement compatibility of human mesenchymal stem cells during clinical infusion into whole blood for treatment of graft-versus-host disease
Moll G, Rasmusson I, Elgue G, Sundberg B, Ekdahl Kn, Le Blanc K, et al
BONE MARROW TRANSPLANTATION 2009;:S161-S162

Composite Endothelial-Mesenchymal Stromal-Islet Cells; A novel angiogenic approach to promote islet revascularization
Johansson U, Rasmusson I, Forslund N, Nilsson B, Korsgren O, Magnusson Pu
XENOTRANSPLANTATION 2007;14(5):405-405

Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes
Rasmusson I, Uhlin M, Le Blanc K, Levitsky V
Journal of leukocyte biology 2007;82(4):887-93

Mesenchymal stem cells stimulate antibody secretion in human B cells
Rasmusson I, Le Blanc K, Sundberg B, Ringdén O
Scandinavian journal of immunology 2007;65(4):336-43

Differences between human fetal and adult multipotent mesenchymal stromal cells (MSC) concerning NK-cell lysis.
Gotherstrom C, Rasmusson I, Le Blanc K
CYTOTHERAPY 2006;

Herpesviruses in mesenchymal stem cells.
Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Leblanc K
CYTOTHERAPY 2006;

Immune modulation by mesenchymal stem cells
Rasmusson I
Experimental cell research 2006;312(12):2169-79

Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual
Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringdén O, Le Blanc K
Bone marrow transplantation 2006;37(11):1051-9

Mesenchymal stem cells for treatment of severe acute graft-versus-host disease
Ringden O, Uzunel M, Rasmusson I, Remberger Me, Sundberg B, Lonnies H, et al
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2006;12(2):2-2

Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, et al
Transplantation 2006;81(10):1390-7

Human mesenchymal stem cells affect IgG production induced by lipopolysaccharide, cytomegalovirus and varicella zoster virus in human spleen
Rasmusson I, Sundberg B, Le Blanc K, Ringden O
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2005;11(2):69-70

Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms
Rasmusson I, Ringdén O, Sundberg B, Le Blanc K
Experimental cell research 2005;305(1):33-41

Human mesenchymal stem cells increase interleukin-2 and soluble IL-2 receptor in mixed lymphocyte cultures
Rasmusson I, Ringden O, Sundberg B, Lonnies L, Le Blanc K
BONE MARROW TRANSPLANTATION 2004;:S87-S87

Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes
Le Blanc K, Rasmusson I, Götherström C, Seidel C, Sundberg B, Sundin M, et al
Scandinavian journal of immunology 2004;60(3):307-15

Mesenchymal stem cells inhibit the expression of IL-2 receptor (CD25) and CD38 on phytohemagglutinin-activated lymphocytes
Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Rosendahl K, et al
BONE MARROW TRANSPLANTATION 2004;:S86-S86

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al
Lancet (London, England) 2004;363(9419):1439-41

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al
BONE MARROW TRANSPLANTATION 2004;:S185-S185

Mesenchymal stem cells inhibit mixed lymphocyte culture but not cell-mediated lympholysis
Le Blanc K, Rasmusson I, Sundberg B, Ringden O
BONE MARROW TRANSPLANTATION 2003;:S246-S246

Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells
Rasmusson I, Ringdén O, Sundberg B, Le Blanc K
Transplantation 2003;76(8):1208-13

Show all publications